Mood alterations in patients treated with chlorambucil

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The alkylating agent chlorambucil produces dose-limiting myelosuppression but can also cause rare central nervous system toxicities, including seizures, when given in high doses. Patients with lymphoma who were receiving intermittent pulsed oral doses of 10-12 mg/m2 chlorambucil per day for 5 days experienced marked mood alterations during therapy. These effects, which have not been reported previously, involved sleep alterations, anxiety and restlessness, irritability, and depression. All effects remitted immediately after the final day of the dosing regimen. Mood alterations should be added to the known list of chlorambucil-related toxicities and can occur with commonly used oral dosing schedules.

Original languageEnglish (US)
Pages (from-to)179-182
Number of pages4
JournalClinical Lymphoma
Volume4
Issue number3
StatePublished - Dec 2003

Fingerprint

Chlorambucil
Psychomotor Agitation
Alkylating Agents
Lymphoma
Appointments and Schedules
Sleep
Seizures
Anxiety
Central Nervous System
Depression
Therapeutics

Keywords

  • Alkylating agents
  • Central nervous system
  • Depression
  • Excitation
  • Neurotoxicity

ASJC Scopus subject areas

  • Cancer Research

Cite this

Mood alterations in patients treated with chlorambucil. / Hehn, Sean T.; Dorr, Robert T; Miller, Thomas P.

In: Clinical Lymphoma, Vol. 4, No. 3, 12.2003, p. 179-182.

Research output: Contribution to journalArticle

@article{7facd32a3f78471fbfc48a32afcddd8e,
title = "Mood alterations in patients treated with chlorambucil",
abstract = "The alkylating agent chlorambucil produces dose-limiting myelosuppression but can also cause rare central nervous system toxicities, including seizures, when given in high doses. Patients with lymphoma who were receiving intermittent pulsed oral doses of 10-12 mg/m2 chlorambucil per day for 5 days experienced marked mood alterations during therapy. These effects, which have not been reported previously, involved sleep alterations, anxiety and restlessness, irritability, and depression. All effects remitted immediately after the final day of the dosing regimen. Mood alterations should be added to the known list of chlorambucil-related toxicities and can occur with commonly used oral dosing schedules.",
keywords = "Alkylating agents, Central nervous system, Depression, Excitation, Neurotoxicity",
author = "Hehn, {Sean T.} and Dorr, {Robert T} and Miller, {Thomas P}",
year = "2003",
month = "12",
language = "English (US)",
volume = "4",
pages = "179--182",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "3",

}

TY - JOUR

T1 - Mood alterations in patients treated with chlorambucil

AU - Hehn, Sean T.

AU - Dorr, Robert T

AU - Miller, Thomas P

PY - 2003/12

Y1 - 2003/12

N2 - The alkylating agent chlorambucil produces dose-limiting myelosuppression but can also cause rare central nervous system toxicities, including seizures, when given in high doses. Patients with lymphoma who were receiving intermittent pulsed oral doses of 10-12 mg/m2 chlorambucil per day for 5 days experienced marked mood alterations during therapy. These effects, which have not been reported previously, involved sleep alterations, anxiety and restlessness, irritability, and depression. All effects remitted immediately after the final day of the dosing regimen. Mood alterations should be added to the known list of chlorambucil-related toxicities and can occur with commonly used oral dosing schedules.

AB - The alkylating agent chlorambucil produces dose-limiting myelosuppression but can also cause rare central nervous system toxicities, including seizures, when given in high doses. Patients with lymphoma who were receiving intermittent pulsed oral doses of 10-12 mg/m2 chlorambucil per day for 5 days experienced marked mood alterations during therapy. These effects, which have not been reported previously, involved sleep alterations, anxiety and restlessness, irritability, and depression. All effects remitted immediately after the final day of the dosing regimen. Mood alterations should be added to the known list of chlorambucil-related toxicities and can occur with commonly used oral dosing schedules.

KW - Alkylating agents

KW - Central nervous system

KW - Depression

KW - Excitation

KW - Neurotoxicity

UR - http://www.scopus.com/inward/record.url?scp=1642422710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642422710&partnerID=8YFLogxK

M3 - Article

C2 - 14715101

AN - SCOPUS:1642422710

VL - 4

SP - 179

EP - 182

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 3

ER -